Physician profile
Medard Sison
NPI 1922507037
$9,746.19
in general payments reported to CMS, 2019-2025
23 companies · $1,665 in 2025
The $1,665 reported for 2025 was more than what 90% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $917 · 2022: $1,664 · 2023: $3,561 · 2024: $1,939 · 2025: $1,665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,164.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,861.64 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $1,674.07 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Alkermes, INC. | $915.97 | 2021-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $804.07 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $802.46 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $783.84 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $552.36 | 2021-2025 | Uzedy, Austedo, Austedo Xr |
| Almatica Pharma LLC | $460.91 | 2022-2024 | Loreev Xr, Sertraline Hcl, Citalopram |
| Indivior INC. | $415.08 | 2022-2023 | Perseris |
| Corium, LLC | $288.69 | 2023-2025 | Azstarys |
| Lundbeck LLC | $285.82 | 2022-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $164.63 | 2024-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $140.87 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $133.31 | 2021-2022 | |
| Tris Pharma INC | $104.71 | 2024-2025 | Dyanavel Xr |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $78.80 | 2021-2024 | Qelbree |
| Biogen, INC. | $73.35 | 2024 | |
| Tempus Ai, INC | $72.12 | 2024 | Tempus Pixel |
| Sunovion Pharmaceuticals INC. | $56.64 | 2021 | |
| Noven Therapeutics, LLC | $21.65 | 2025 | Xelstrym |
| Sun Pharmaceutical Industries INC. | $20.68 | 2021 | |
| Neuronetics, INC. | $17.37 | 2023 | Neurostar Tms Therapy System |
| Collegium Pharmaceutical, INC. | $17.15 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Medard Sison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.